Market Overview

Goldman Sachs Downgrades Aetna To Neutral

Share:
Related AET
Managed Care Stocks Might Be The Best Defense Against Market Volatility
Jim Cramer Gives His Opinion On Humana, Alibaba And General Electric
Catasys: Promising 2Q 2015 Results With Potential For Significant Growth (Seeking Alpha)

Analysts at Goldman Sachs downgraded Aetna (NYSE: AET) from Buy to Neutral.

The target price for Aetna has been lowered from $94.00 to $88.00.

Aetna shares have surged 24.00% over the past 52 weeks, while the S&P 500 index has gained 13.56% in the same period.

Aetna's shares dropped 0.61% to $77.84 in pre-market trading.

Latest Ratings for AET

DateFirmActionFromTo
Jul 2015Bank of AmericaUpgradesNeutralBuy
Jul 2015FBR CapitalDowngradesOutperformMarket Perform
Jul 2015BarclaysMaintainsOverweight

View More Analyst Ratings for AET
View the Latest Analyst Ratings

Posted-In: Goldman SachsDowngrades Analyst Ratings

 

Related Articles (AET)

Get Benzinga's Newsletters